Intellia Therapeutics (FRA:38I) Cyclically Adjusted Revenue per Share: €0.72 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:38I Intellia Therapeutics Inc FRA:38I
65 GF Score
Price €9.27
GF Value €17.88
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Cyclically Adjusted Revenue per Share?

Intellia Therapeutics FRA:38I -3.54% 65 Cyclically Adjusted Revenue per Share is €0.72 as of Mar. 2026. GuruFocus rates FRA:38I with a GF Score™ of 65/100 and a GF Value™ of €17.88 (Possible Value Trap). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Intellia Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was €0.110. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €0.72 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Intellia Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 5.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-28), Intellia Therapeutics's current stock price is €9.27. Intellia Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €0.72. Intellia Therapeutics's Cyclically Adjusted PS Ratio of today is 12.88.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Intellia Therapeutics was 32.00. The lowest was 8.39. And the median was 15.08.


Intellia Therapeutics  (FRA:38I) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Intellia Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=9.27/0.72
=12.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PS Ratio of Intellia Therapeutics was 32.00. The lowest was 8.39. And the median was 15.08.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Intellia Therapeutics Cyclically Adjusted Revenue per Share Related Terms


Intellia Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Cyclically Adjusted Revenue per Share Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.73 0.67

Intellia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.74 0.73 0.70 0.67 0.72

FRA:38I vs SEPN, AVBP, VIR: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Intellia Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intellia Therapeutics Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Intellia Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Intellia Therapeutics's Cyclically Adjusted PS Ratio falls into.


FRA:38I
65GF Score
Intellia Therapeutics Inc FRA:38I
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Intellia Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.11/330.2130*330.2130
=0.110

Current CPI (Mar. 2026) = 330.2130.

Intellia Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.196 241.018 0.269
201609 0.126 241.428 0.172
201612 0.148 241.432 0.202
201703 0.167 243.801 0.226
201706 0.151 244.955 0.204
201709 0.174 246.819 0.233
201712 0.144 246.524 0.193
201803 0.144 249.554 0.191
201806 0.153 251.989 0.200
201809 0.147 252.439 0.192
201812 0.157 251.233 0.206
201903 0.204 254.202 0.265
201906 0.215 256.143 0.277
201909 0.199 256.759 0.256
201912 0.199 256.974 0.256
202003 0.232 258.115 0.297
202006 0.271 257.797 0.347
202009 0.321 260.280 0.407
202012 0.088 260.474 0.112
202103 0.081 264.877 0.101
202106 0.080 271.696 0.097
202109 0.083 274.310 0.100
202112 0.153 278.802 0.181
202203 0.137 287.504 0.157
202206 0.175 296.311 0.195
202209 0.176 296.808 0.196
202212 0.147 296.797 0.164
202303 0.134 301.836 0.147
202306 0.142 305.109 0.154
202309 0.127 307.789 0.136
202312 -0.019 306.746 -0.020
202403 0.279 312.332 0.295
202406 0.067 314.175 0.070
202409 0.081 315.301 0.085
202412 0.121 315.605 0.127
202503 0.149 319.799 0.154
202506 0.119 322.561 0.122
202509 0.107 324.800 0.109
202512 0.169 324.054 0.172
202603 0.110 330.213 0.110

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €0.72 mean?
Intellia Therapeutics (FRA:38I) has a Cyclically Adjusted Revenue per Share of €0.72 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Cyclically Adjusted Revenue per Share too high?
Intellia Therapeutics' current Cyclically Adjusted Revenue per Share is €0.72. Overall, Intellia Therapeutics has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Cyclically Adjusted Revenue per Share compare to SEPN and AVBP?
Intellia Therapeutics' Cyclically Adjusted Revenue per Share of €0.72 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Cyclically Adjusted Revenue per Share is €0.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (FRA:38I) is currently considered Possible Value Trap. The stock's GF Value™ is €17.88, compared to a current price of €9.27 — trading 48.2% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €0.72. Intellia Therapeutics' overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Intellia Therapeutics (FRA:38I), the current Cyclically Adjusted Revenue per Share is €0.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (FRA:38I) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of €9.27 is trading 48.2% below its estimated GF Value™ of €17.88. GuruFocus considers Intellia Therapeutics to be Possible Value Trap.

Key valuation signals for FRA:38I:

  • Cyclically Adjusted Revenue per Share: €0.72
  • GF Value™: €17.88 vs. price of €9.27 (48.2% below fair value)
  • GF Score™: 65/100 with 5 warning signs

No single metric tells the full story. See the FRA:38I stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Intellia Therapeutics Business Description

Other Exchanges NTLA:USA0JBU:UK38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
65GF Score

Get the complete analysis for FRA:38I

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.27
Price
€17.88
GF Value